IP Library › Granted Patent US 12,533,398
Granted Patent B2
US 12,533,398 · App. 18/818,465 · Granted Jan 27, 2026

Process, tube and device for the preparation of wound healant composition

Inventor: Antoine Turzi (Lauenen b. Gstaad, CH)
Assignee: RegenLab USA LLC
A61K38/4833A61K8/981A61K8/983A61K31/728A61K35/14A61K35/15A61K35/16A61K35/17A61K35/18A61K35/19A61K38/363A61L26/0057A61L26/0066A61M1/0209A61M1/029A61M5/19A61Q19/08C12Y304/21005A61L2300/30A61L2300/412A61M2202/0425A61M2202/0427
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,533,398
App. No.
18/818,465
Granted
Jan 27, 2026
Kind
B2
Abstract

The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

Claims (23)

1 . A method of treating a patient, the method comprising:

providing a system for the preparation of a cell composition of platelet rich plasma and hyaluronic acid, the system comprising:

a tube having:

an anticoagulant adapted to reduce coagulation of whole blood; and

a hyaluronic acid, wherein prior to introduction of the whole blood into the tube, the anticoagulant and the hyaluronic acid are at least partially filled in the tube with the hyaluronic acid beneath the anticoagulant, and wherein during centrifugation the hyaluronic acid migrates above the platelet rich plasma;

the tube sterilized with the hyaluronic acid and hermetically sealed;

the tube adapted to receive the whole blood while maintaining sterility; and

the tube adapted to be centrifuged for a length of time in order to separate platelet rich plasma from the whole blood, and to prepare the cell composition including the platelet rich plasma and the hyaluronic acid in the tube;

withdrawing the whole blood from the patient;

centrifuging the whole blood in the tube to form the cell composition including the platelet rich plasma and the hyaluronic acid; and

administering the cell composition to the patient;

wherein the platelet rich plasma is autologous.

2 . The method of claim 1 , further comprising re-suspending the platelet rich plasma in the tube prior to administering.

3 . The method of claim 1 , wherein the centrifuging is performed at a force between about 1000 g and up to about 2000 g for a time selected from about 3 minutes up to about 7 minutes.

4 . The method of claim 1 , wherein the centrifuging is performed at a force between about 1500 g to about 2000 g for about 3 to 10 minutes.

5 . The method of claim 1 , wherein the centrifuging is performed at a force of at least 1500 g for at least 8 minutes.

6 . The method of claim 1 , wherein the administering comprises:

filling a skin scar, a wrinkle line, or a fat deficiency of the patient with the cell composition.

7 . The method of claim 1 , wherein the tube is sealed with a cap under vacuum pressure to aspirate the whole blood from a patient during the withdrawing.

8 . The method of claim 1 , wherein the tube further comprises at least one thixotropic gel.

9 . The method of claim 8 , wherein the hyaluronic acid is layered beneath the at least one thixotropic gel, and wherein the at least one thixotropic gel is layered beneath the anticoagulant.

10 . The method of claim 9 , wherein the layers of hyaluronic acid, at least one thixotropic gel, and anticoagulant migrate across each other upon centrifugation of the tube.

11 . The method of claim 1 , wherein the tube further comprises sodium citrate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2024
From: TURZI, ANTOINE
To: REGENLAB USA LLC
Reel/Frame 068500/0580 →
Priority Claims (1)
GB 1004072 · Mar 11, 2010 · national
Continuity (6)
Division 16298112 · Mar 11, 2019
Continuation 15886699 · Feb 1, 2018
Continuation 15373506 · Dec 9, 2016
Division 14596268 · Jan 14, 2015
Division 13634020
Related Publication 20240415941A1 · Dec 19, 2024
References Cited (69)
US 3852194A · Zine, Jr. · 1974 [cited by applicant]
US 4101422A · Lamont et al. · 1978 [cited by applicant]
US 4148764A · Lamont et al. · 1979 [cited by applicant]
US 4190535A · Luderer et al. · 1980 [cited by applicant]
US 4350593A · Kessler · 1982 [cited by applicant]
US 4946601A · Fiehler · 1990 [cited by applicant]
US 5236604A · Fiehler · 1993 [cited by applicant]
US 5631011A · Wadstrom · 1997 [cited by applicant]
US 5667963A · Smith et al. · 1997 [cited by applicant]
US 5906744A · Carroll et al. · 1999 [cited by applicant]
US 6472162B1 · Coelho et al. · 2002 [cited by applicant]
US 6979307B2 · Beretta et al. · 2005 [cited by applicant]
US 7094464B2 · Mao et al. · 2006 [cited by applicant]
US 8491564B2 · Beretta et al. · 2013 [cited by applicant]
US 10092598B2 · Turzi et al. · 2018 [cited by applicant]
US 20020187130A1 · Kindness et al. · 2002 [cited by applicant]
US 20040151709A1 · Gorrochategui Barrueta et al. · 2004 [cited by applicant]
US 20050170327A1 · Sumida et al. · 2005 [cited by applicant]
US 20090317439A1 · Turzi · 2009 [cited by examiner]
US 20100196497A1 · Lim · 2010 [cited by examiner]
CA 2181462C · 1996 [cited by applicant]
CH 696752A5 · 2007 [cited by applicant]
WO 1999066923A1 · 1999 [cited by applicant]
WO 2008022651A1 · 2008 [cited by applicant]
WO 2008023026A2 · 2008 [cited by applicant]
“Autologous PRP” RegenLab, May 2, 2006, pp. 1-2. https://web.archive.org/web/20060502171522/http://www.regenkit.com/products.html. [cited by applicant]
“BD Vacutainer CPT—Cell Preparation Tube with Sodium Citrate”, Beckton, Dickinson and Co., (2003), pp. 1-14. [cited by applicant]
“BD Vacutainer Tube Guide”, Beckton, Dickinson and Co., published 2006, pp. 1-8. http://www.bd.com/resource.aspx?IDX=11068. [cited by applicant]
“Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing”, ClinicalTrials. gov, 46 pages. https://clinicaltrials.gov/study/NCT00856934?term=platelet%20rich%20plasma%20and%20keratinocyte&rank=2&a=1. [cited by applicant]
“Regen Lab: Products for Tissue Repair”, Regan Lab, Apr. 2006, pp. 1-2. https://web-beta.archive.org/web/20060426121922://http://www.regenkit.com/. [cited by applicant]
“RegenPRP-Kit Medical Device IIa CE1250”, RegenLab Geneve, Sep. 26, 2004, pp. 1-17. https://web.archive.org/web/20050313100219/http://www.regenkit.com/docs/RegenPRP-Kit_ang.pdf. [cited by applicant]
2003 Swiss Assoc. for Quality and Management Systems, IQNet certificate, Risk analysis, contract, pp. 1-34. [cited by applicant]
Carr, M. E. et al. “Permeability of hyaluronic acid solutions” Arthritis and Rheumatism, Dec. 1980, pp. 1371-1375, vol. 23, No. 12. [cited by applicant]
Charles F. Arkin et al: “Tubes and Additives for Venous Blood Specimen Collection; Approved Standard-Fifth Edition”, NCCLS document H1-A5, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA; 2003, vol.… [cited by applicant]
Chen, G. et al. “Photoimmobilization of Sulfated Hyaluronic Acide for Antithrombogenicty” Bioconjugate Chemistry, Sep. 25, 1997, pp. 730-734, vol. 8, No. 5. [cited by applicant]
De Oliveira & Saldanha. “An overview about erythrocyte membrane”. Clinical Hemorheology and Microcirculation, Institute of Molecular Medicine, Lisbon, Portugal, published 2010, vol. 44, pp. 63-74. [cited by applicant]
Du Toit DF, et al.: “Soft and hard-tissue augmentation with platelet-rich plasma: Tissue culture dynamics, egeneration and molecular biology perspective”, International Journal of Shoulder Surgery, published 2007, vol. … [cited by applicant]
Everts et al.: “Platelet rich plasma and platelet gel, A review.”, Journal of Extra-Corporeal Technology, Orlando FL, USA, published May 18, 2006, vol. 38, pp. 174-187. [cited by applicant]
Gadol et al.: “A new method for separating mononuclear cell from whole blood” Diagnostic Immunology, published 1985; vol. 3, Issue No. 3, pp. 145-154. https://www.ncbi.nlm.nih.gov/pubmed/3931958. [cited by applicant]
Garratty, Telen & Petz: “Red Cell Antigens as Functional Molecules and Obstacles to Transfusion, Part I. Erythrocyte Blood Group Antigens: Physiologic and Pathologic Functions of Red Cell Antigen-Bearing Molecules”, by … [cited by applicant]
Gong et al. International J of polymer science, 2010, p. 1-8. [cited by applicant]
Graziani et al.: “The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts”, Clinical Oral Implants Research, published Apr. 2006, vol. 17, issue No. 2, pp. 212-219. [cited by applicant]
J.R. Storry: “Review: the function of blood group-specific RBC membrane components”, Immunohematology Journal of Blood Group Serology and Education, published 2004, vol. No. 20, issue No. 4, pp. 206-216. [cited by applicant]
Laurens, I.: “Development of a new extraction method for platelet-rich plasma and partial purification of platelet-derived growth factor and transforming growth factor beta”. Dissertation submitted in fulfillment of the… [cited by applicant]
Mason, M. et al. “Attachment of hyaluronic acid to polypropylene, polystyrene, and polytetrafluoroethylene” Biomaterials, 2000, pp. 31-36, vol. 21. [cited by applicant]
Okabe, K. et al. “Injectable soft-tissue augmentation by tissue engineering and regenerative medicine with human rnesenchymal stromal cells, platelet-rich plasma and hyaluronic acid scaffolds” Cytotherapy, 2009, pp. 307… [cited by applicant]
Perttila, J. et al.: “Plasma Fibronectin concentrations in blood products”, Intensive Care Med., published Jan. 1990, vol. 16, issue No. 1, pp. 41-43; ISSN 1432-1238. https://doi.org/10.1007/BF01706323. [cited by applicant]
Raffoul, et al.: “Impact of platelets concentrate and keratinocyte suspension on wound healing—a prospective andomized trial”, The International Journal of Artificial Organs, published 2008, pp. 1-16. [cited by applicant]
Regen Lab brochure entitled RegenPRP-Kit available at www.regenkit.com as of May 2, 2006. Obtained from archived version of May 2, 2006 on the Wayback Machine, pp. 1-17 http://web.archive.org/web/20060502171406/http://w… [cited by applicant]
Regen Lab Presentation, “Innovation in Biological Tissue Regeneration”, 2005, pp. 1-54. [cited by applicant]
Regen Lab Webpage available at www.regenkit.com, as of May 2, 2006 https://web.archive.org/web/20060502171344/http://regenkit.com:80/company.html. [cited by applicant]
Regen Lab webpage available at www.regenkit.com as of May 16, 2006 https://web.archive.org/web/20060516102752http://www.regenkit.com:80/regen_THT.html. [cited by applicant]
Regen-Kit Instructions for Use, May 2, 2006, pp. 1-2. https://web.archive.org/web/20060502171707/http:/www.regenkit.com/doc/RegenPRP-Kit-IFU.pdf. [cited by applicant]
RegenLab Certification from Swiss Association for Quality and management Systems (SQS) for the developing and marketing of medical devices, Feb. 21, 2005, and Regen Lab CE Certification “X(1250” for the Regen Kit under … [cited by applicant]
Research Study, Comparison of EmCyte GS30-PurePRP® II, EmCyte GS60-PurePRP® II, Arteriocyte Magellan, Stryker Regenkit® THT, and Eclipse Prp. Principle Investigator Robert Mandie, PhD, Biosciences Research Associates, C… [cited by applicant]
Slighter et al.: “Plalelet Transfusion Therapy”, Chapter 14 in “Platelets In Hematologic And Cardiovascular Disorders”. Edited by Paolo Gresele et al.; Cambridge University Press, Cambridge United Kingdom, 2008, pp. 242… [cited by applicant]
Sloan, et al., Biochemical Society Transactions, 1996, 24, 103S. [cited by applicant]
Sumide et al. J. Pharmacol., 2006, 101:91-97. [cited by applicant]
Translation Swiss 2003 Assoc. and Management Systems, IQNet certificate, Risk analysis, contract, pp. 23-24. [cited by applicant]
Tsay et al.: “Differential growth factor retention by platelet-rich plasma composites”, Journal of Oral and Maxillofacial Surgery, vol. No. 63, Issue No. 4, 2005, pp. 521-528, ISSN 0278-2391, http://www.sciencedirecl.co… [cited by applicant]
Van Laethem et al.: “Diagnosis of human immunodeficiency virus infection by a polymerase chain assay evaluated in patents harbouring strains of diverse geographical origin” Journal of Virological Methods, published Feb.… [cited by applicant]
Wiwanitkit, Songkla Med J., 2002, 20(4):301-305. [cited by applicant]
Written Opinion in International Application No. PCT/IB2011/000684, Jan. 30, 2012, pp. 1-12. [cited by applicant]
U.S. Office Action, U.S. Appl. No. 15/373,506, Mailed: Jan. 17, 2018, 6 pages. [cited by applicant]
U.S. Office Action, U.S. Appl. No. 15/044,498, Mailed: Feb. 5, 2018, 13 pages. [cited by applicant]
U.S. Office Action, U.S. Appl. No. 15/886,699, Mailed: Apr. 19, 2018, 6 Pages. [cited by applicant]
U.S. Office Action, U.S. Appl. No. 15/886,699, Mailed: Jun. 28, 2018, 10 Pages. [cited by applicant]
U.S. Office Action, U.S. Appl. No. 15/373,506, Mailed: Aug. 28, 2018, 11 Pages. [cited by applicant]
U.S. Office Action, U.S. Appl. No. 15/886,699, Mailed: Nov. 19, 2018, 11 Pages. [cited by applicant]